Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.
Authors
Richard S. Finn
David Geffen School of Medicine at UCLA, UCLA Medical Center, Los Angeles, CA;
Richard S. Finn , Philippe Merle , Masafumi Ikeda , Heinz-Josef Klümpen , Gianluca Masi , Alessandro Granito , Ho Yeong Lim , Masatoshi Kudo , Shukui Qin , René Gerolami , Yi-Hsiang Huang , Do Young Kim , Matthias Pinter , Naoya Kato , Masayuki Kurosaki , Kazushi Numata , Javeed Khan , Kirhan Ozgurdal , Yoon Jun Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
NCT03289273
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 518)
DOI
10.1200/JCO.2023.41.4_suppl.518
Abstract #
518
Poster Bd #
B8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study.
First Author: Richard S. Finn
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Contemporary real-world evidence in unresectable HCC (uHCC) patients treated with regorafenib in Taiwan: Interim results from the observational REFINE study.
First Author: Shi-Ming Lin
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) and Child–Pugh (CP)-B liver function treated with regorafenib in routine clinical practice in the observational REFINE study.
First Author: Yoon Jun Kim
Poster
2017 Gastrointestinal Cancers Symposium
Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial.
First Author: Richard S. Finn